David R holmes Holmes

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Incidence of late stent thrombosis with bare-metal, sirolimus, and paclitaxel stents
    David R Holmes
    Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA
    Rev Cardiovasc Med 8:S11-8. 2007
  2. ncbi request reprint Creativity, ingenuity, serendipity
    David R holmes Holmes
    Mayo Clinic, Rochester, Minnesota, USA
    Can J Cardiol 21:1061-5. 2005
  3. ncbi request reprint Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial
    David R Holmes
    Mayo Clinic, Rochester, Minnesota Electronic address
    J Am Coll Cardiol 64:1-12. 2014
  4. pmc Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers
    Brendan Doyle
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Med Devices (Auckl) 2:47-55. 2009
  5. pmc Pharmacogenomic testing and antithrombotic therapy: ready for prime time?
    David R Holmes
    Past President, American College of Cardiology ACC Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
    Rambam Maimonides Med J 4:e0005. 2013
  6. doi request reprint Left atrial appendage occlusion: opportunities and challenges
    David R Holmes
    Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota Electronic address
    J Am Coll Cardiol 63:291-8. 2014
  7. doi request reprint The heart team of cardiovascular care
    David R Holmes
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    J Am Coll Cardiol 61:903-7. 2013
  8. pmc Time course analysis of gene expression identifies multiple genes with differential expression in patients with in-stent restenosis
    Santhi K Ganesh
    National Heart, Lung, and Blood Institute NHLBI, Division of Intramural Research, Bethesda, Maryland, USA
    BMC Med Genomics 4:20. 2011
  9. ncbi request reprint Thrombosis and drug-eluting stents: an objective appraisal
    David R Holmes
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55955, USA
    J Am Coll Cardiol 50:109-18. 2007
  10. ncbi request reprint Medical devices and pharmaceuticals: differences in public acceptance
    David R Holmes
    Mayo Clinic, Rochester, MN 55905, USA
    Am Heart Hosp J 4:269-72. 2006

Detail Information

Publications77

  1. ncbi request reprint Incidence of late stent thrombosis with bare-metal, sirolimus, and paclitaxel stents
    David R Holmes
    Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA
    Rev Cardiovasc Med 8:S11-8. 2007
    ..Newer strategies being evaluated to enhance the safety of drug-eluting stents include different alloys and stent designs, revisions in the polymer or drug utilized, and, ultimately, bioabsorbable platforms...
  2. ncbi request reprint Creativity, ingenuity, serendipity
    David R holmes Holmes
    Mayo Clinic, Rochester, Minnesota, USA
    Can J Cardiol 21:1061-5. 2005
    ..An increased knowledge of the basic pathophysiology of cardiovascular disease, combined with creative technology and imaginative operators, will continue to advance the field...
  3. ncbi request reprint Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial
    David R Holmes
    Mayo Clinic, Rochester, Minnesota Electronic address
    J Am Coll Cardiol 64:1-12. 2014
    ....
  4. pmc Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers
    Brendan Doyle
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Med Devices (Auckl) 2:47-55. 2009
    ..Too good to be true? We explore here the scientific rationale and prospects for success with this exciting concept...
  5. pmc Pharmacogenomic testing and antithrombotic therapy: ready for prime time?
    David R Holmes
    Past President, American College of Cardiology ACC Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
    Rambam Maimonides Med J 4:e0005. 2013
    ..This article also discusses developments in the field of anti-clotting therapy since the FDA's warning. ..
  6. doi request reprint Left atrial appendage occlusion: opportunities and challenges
    David R Holmes
    Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota Electronic address
    J Am Coll Cardiol 63:291-8. 2014
    ....
  7. doi request reprint The heart team of cardiovascular care
    David R Holmes
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    J Am Coll Cardiol 61:903-7. 2013
    ..While specific strategies for implementation of these teams will vary, this broad approach will become the standard of cardiovascular care...
  8. pmc Time course analysis of gene expression identifies multiple genes with differential expression in patients with in-stent restenosis
    Santhi K Ganesh
    National Heart, Lung, and Blood Institute NHLBI, Division of Intramural Research, Bethesda, Maryland, USA
    BMC Med Genomics 4:20. 2011
    ..We hypothesized that the analysis of gene expression in peripheral blood mononuclear cells (PBMCs) would demonstrate differences in transcript expression between individuals who develop ISR and those who do not...
  9. ncbi request reprint Thrombosis and drug-eluting stents: an objective appraisal
    David R Holmes
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55955, USA
    J Am Coll Cardiol 50:109-18. 2007
    ....
  10. ncbi request reprint Medical devices and pharmaceuticals: differences in public acceptance
    David R Holmes
    Mayo Clinic, Rochester, MN 55905, USA
    Am Heart Hosp J 4:269-72. 2006
    ....
  11. ncbi request reprint The 5-year projection on the future of interventional cardiology
    David R Holmes
    Mayo Clinic, Rochester, MN 55905, USA
    Am Heart Hosp J 4:195-201. 2006
    ..This revolution continues to gather speed. Creative solutions continue to be proposed, evaluated, and then brought to the patient care arena. Issues remain, but these identify opportunities for continuing improvement...
  12. doi request reprint 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial
    David R Holmes
    Department of Cardiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    JACC Cardiovasc Interv 1:439-48. 2008
    ..The aim of this study was to evaluate long-term outcome of patients treated for in-stent restenosis of bare-metal stents (BMS)...
  13. ncbi request reprint Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial
    David R Holmes
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA
    JAMA 295:1264-73. 2006
    ..Although vascular brachytherapy is the only approved therapy for restenosis following bare-metal stent implantation, drug-eluting stents are now being used. Data on the relative merits of each are limited...
  14. ncbi request reprint Antiplatelet therapy after percutaneous coronary intervention
    David R Holmes
    Mayo Clinic, Rochester, MN 55905, USA
    Cerebrovasc Dis 21:25-34. 2006
    ..In the future, more individually targeted therapy may be possible if we can more adequately assess the degree of hyperreactivity and underlying inflammation...
  15. ncbi request reprint Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique
    David R Holmes
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Catheter Cardiovasc Interv 66:375-89. 2005
    ..For optimal results, patients need to be selected after catheter assessment and combined echocardiography and angiography, and ablation techniques need to be scientific and rigorous...
  16. ncbi request reprint Renal and iliac artery stenting by interventional cardiologists and vascular surgeons: the Foundation to Advance Medical Education (FAME) initiative
    David R Holmes
    Internal Medicine and Cardiovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA
    Am Heart J 149:883-7. 2005
    ..Programs such as the FAME initiative will grow in importance as new technologies continue to be introduced into medical practice and the need to train physicians in practice in their use expands...
  17. ncbi request reprint What the future holds for the diagnosis and management of patients with acute myocardial infarction
    David R Holmes
    Mayo Clinic, Cardiovascular Diseases and Internal Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Med Clin North Am 91:787-90. 2007
    ..Important issues remain to be resolved, many of which have been explored in this book...
  18. doi request reprint Not only is it safe but it is also effective
    David R Holmes
    Mayo Clinic College of Medinine, Rochester, Minnesota 55905, USA
    Catheter Cardiovasc Interv 71:474. 2008
  19. doi request reprint Evolving challenges in medical device evaluation
    David R Holmes
    Internal Medicine and Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Catheter Cardiovasc Interv 72:1-6. 2008
  20. doi request reprint Atrial fibrillation and stroke management: present and future
    David R Holmes
    Department of Internal Medicine and Cardiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Semin Neurol 30:528-36. 2010
    ..New randomized trials and registries continue to explore the potential for device placement as an alternative to anticoagulant therapy for stroke prevention in this group of patients...
  21. doi request reprint Stent thrombosis
    David R Holmes
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 56:1357-65. 2010
    ..The goal remains identification of patients at particularly increased risk of ST so that optimal prevention strategies can be developed and employed...
  22. ncbi request reprint Circadian rhythms in patients with ST-elevation myocardial infarction
    David R Holmes
    Mayo Clinic, Rochester, MN 55905, USA
    Circ Cardiovasc Qual Outcomes 3:382-9. 2010
    ..We evaluated these rhythms in patients with ST-elevation myocardial infarction as a function of the 24-hour circadian cycle...
  23. doi request reprint Catheter-based treatment of coronary artery disease: past, present, and future
    David R Holmes
    Mayo Clinic, Rochester, MN 55901, USA
    Circ Cardiovasc Interv 1:60-73. 2008
    ..These approaches will continue to be of paramount importance as new technologies are brought to bear on an increasingly broader group of patients with cardiovascular disease...
  24. doi request reprint Iatrogenic pericardial effusion and tamponade in the percutaneous intracardiac intervention era
    David R Holmes
    Mayo Clinic, Rochester, Minnesota 55905, USA
    JACC Cardiovasc Interv 2:705-17. 2009
    ..Collaboration with noninvasive colleagues and training interventionalists who perform intracardiac interventions, both electrophysiologists and interventional cardiologists, should be required as part of every invasive program...
  25. doi request reprint Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
    David R Holmes
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Lancet 374:534-42. 2009
    ..We assessed the efficacy and safety of percutaneous closure of the LAA for prevention of stroke compared with warfarin treatment in patients with atrial fibrillation...
  26. ncbi request reprint Combining antiplatelet and anticoagulant therapies
    David R Holmes
    Mayo Clinic Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Am Coll Cardiol 54:95-109. 2009
    ..It is both prudent and timely to review treatment strategies that employ combinations of antiplatelet and anticoagulant therapies as well as strategies aimed at reducing bleeding risk in patients treated with these therapies...
  27. doi request reprint Pulmonary vein stenosis complicating ablation for atrial fibrillation: clinical spectrum and interventional considerations
    David R Holmes
    Department of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    JACC Cardiovasc Interv 2:267-76. 2009
    ..Follow-up of these patients typically involves computed tomography imaging to document restenosis. If significant restenosis is identified, it should be treated promptly because of the potential for progression to total occlusion...
  28. doi request reprint Percutaneous coronary intervention for chronic stable angina: a reassessment
    David R Holmes
    Department of Cardiology, Division of Cardiovascular Disease and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    JACC Cardiovasc Interv 1:34-43. 2008
    ..The appropriate utilization rates of PCI in patients with chronic stable angina and preserved left ventricular function should lead to more cost-effective care of patients with stable CAD...
  29. ncbi request reprint Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met?
    David R Holmes
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 151:779-85. 2006
    ..Reperfusion therapy for acute myocardial infarction has revolutionized modern cardiovascular care...
  30. ncbi request reprint Strokes and holes and headaches: are they a package deal?
    David R Holmes
    Mayo Clinic, Rochester, MN 55905, USA
    Lancet 364:1840-2. 2004
  31. ncbi request reprint Paradigm shifts in cardiovascular medicine
    David R Holmes
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 43:507-12. 2004
    ..replacement of major surgical procedures with less invasive approaches; and 2). redistribution of costs, with a decrease in hospital profits but potentially lower costs of health care delivery for society as a whole...
  32. ncbi request reprint Conflict of interest
    David R Holmes
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Am Heart J 147:228-37. 2004
    ....
  33. ncbi request reprint How many grails do we need?
    David R Holmes
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, Minn 55905, USA
    Circulation 109:2158-9. 2004
  34. doi request reprint Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort
    Pieter J Vlaar
    Division of Cardiovascular Disease and Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Catheter Cardiovasc Interv 71:764-9. 2008
    ..The objective of this study is to investigate the clinical outcome of a large cohort of patients with ST-segment elevation myocardial infarction (STEMI) treated with drug-eluting stents (DES) compared to bare metal stents (BMS)...
  35. ncbi request reprint Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention
    Charanjit S Rihal
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 105:2259-64. 2002
    ..In patients undergoing percutaneous coronary intervention (PCI) in the modern era, the incidence and prognostic implications of acute renal failure (ARF) are unknown...
  36. doi request reprint Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005
    Brendan J Doyle
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    JACC Cardiovasc Interv 1:202-9. 2008
    ....
  37. doi request reprint Temporal trends and improved outcomes of percutaneous coronary revascularization in nonagenarians
    Aaron M From
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, Minnesota, USA
    JACC Cardiovasc Interv 1:692-8. 2008
    ..The aim of this study was to describe the clinical characteristics and the outcomes of patients 90 years of age or older who were treated with percutaneous coronary intervention (PCI)...
  38. ncbi request reprint Cutting balloon angioplasty vs. conventional balloon angioplasty in patients receiving intracoronary brachytherapy for the treatment of in-stent restenosis
    Panayotis Fasseas
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Catheter Cardiovasc Interv 63:152-7. 2004
    ....
  39. ncbi request reprint Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation
    James L Orford
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA
    Am Heart J 147:463-7. 2004
    ..We sought to determine the frequency and type of hemorrhagic complications in patients who undergo systemic anticoagulation with warfarin while receiving aspirin and clopidogrel after a PCI with stent placement...
  40. ncbi request reprint Safety and efficacy of cutting balloon angioplasty: the Mayo Clinic experience
    James L Orford
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Invasive Cardiol 14:720-4. 2002
    ..A number of evolving clinical indications for cutting balloon angioplasty (CBA) have been described in the clinical literature, including angioplasty-resistant stenoses, in-stent restenosis, ostial lesions and small vessel disease...
  41. ncbi request reprint Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial
    Patricia J M Best
    Mayo Clinic, Rochester, Minnesota, USA
    J Am Coll Cardiol 44:1786-91. 2004
    ..The goal of this study was to determine if restenosis is increased in mild and moderate chronic kidney disease (CKD) patients after percutaneous coronary intervention (PCI)...
  42. ncbi request reprint The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation
    David R Holmes
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn, USA
    J Thorac Cardiovasc Surg 134:38-46, 46.e1. 2007
    ..Evaluation of cause of death might help elucidate disease mechanisms and be useful for developing treatment strategies...
  43. ncbi request reprint Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS)
    Mandeep Singh
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 107:2331-6. 2003
    ..Acolysis (therapeutic ultrasound) can break up thrombus in vitro in animal models and humans. Whether this is beneficial during percutaneous SVG interventions is unknown...
  44. ncbi request reprint Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events
    Paul V Targonski
    Division of Community Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Circulation 107:2805-9. 2003
    ..However, the magnitude of the association between coronary endothelial dysfunction (CED) and cerebrovascular events is unknown. This study was performed to investigate the association between CED and cerebrovascular events...
  45. ncbi request reprint Association of body mass index with outcome after percutaneous coronary intervention
    Brian D Powell
    Division of Cardiovascular Diseases and Internal Medicine and Section of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Cardiol 91:472-6. 2003
  46. pmc Clinical risk stratification in the emergency department predicts long-term cardiovascular outcomes in a population-based cohort presenting with acute chest pain: primary results of the Olmsted county chest pain study
    Michael E Farkouh
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Medicine (Baltimore) 88:307-13. 2009
    ..This algorithm, when applied in the ED, affords an excellent opportunity to identify patients who might benefit from a more aggressive cardiovascular risk factor management strategy...
  47. ncbi request reprint Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy
    Uma S Valeti
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
    J Am Coll Cardiol 49:350-7. 2007
    ..This study sought to describe the acute morphologic differences that result from septal myectomy and alcohol septal ablation using cardiac magnetic resonance (CMR) imaging...
  48. ncbi request reprint Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry
    James L Orford
    Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Am Coll Cardiol 40:1567-72. 2002
    ..The study examined the frequency, correlates, and outcome of patients with stent thrombosis within 30 days of stent placement...
  49. ncbi request reprint The future of interventional cardiology
    David R Holmes
    Mayo Clinic, 200 First Street SW, SMH MB 4 523, Rochester, Minnesota 55905, USA
    J Cardiol 49:59-62. 2007
  50. ncbi request reprint Effect of lesion length on fractional flow reserve in intermediate coronary lesions
    David Brosh
    Cardiovascular Division, Mayo Clinic Foundation, Rochester, MN 55902, USA
    Am Heart J 150:338-43. 2005
    ..However, the effect of LL on FFR has not been adequately assessed. We sought to evaluate the effect of LL on FFR in patients with angiographically intermediate coronary artery disease...
  51. ncbi request reprint Proteinuria, serum creatinine, and outcome of percutaneous coronary intervention in patients with diabetes mellitus
    Guy S Reeder
    Division of Cardiovascular Disease, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Am J Cardiol 89:760-4. 2002
  52. ncbi request reprint Routine intravascular ultrasound scanning guidance of coronary stenting is not associated with improved clinical outcomes
    James L Orford
    Division of Cardiovascular Medicine and Department of Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Am Heart J 148:501-6. 2004
    ..The purpose of the current study was to determine whether there is any incremental benefit to routine intravascular ultrasound (IVUS) guidance of percutaneous coronary intervention...
  53. ncbi request reprint Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions
    Patricia J M Best
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Am Heart J 146:345-50. 2003
    ..Abciximab reduces complications, but may cause excessive bleeding in patients with CRI. Therefore, we sought to determine the safety of abciximab in patients with CRI...
  54. ncbi request reprint Strain rate imaging for assessment of regional myocardial function: results from a clinical model of septal ablation
    Theodore P Abraham
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 105:1403-6. 2002
    ..We examined regional myocardial function using TDI and SRI in a unique clinical model of a small, discrete myocardial infarction...
  55. ncbi request reprint Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials
    Abhiram Prasad
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur Heart J 24:1544-53. 2003
    ..The choice of one approach over another is guided largely by local practice patterns and the availability of invasive facilities...
  56. ncbi request reprint Relation of Thrombolysis in Myocardial Infarction (TIMI) frame count to coronary flow parameters
    Cem Barcin
    Division of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Cardiol 91:466-9. 2003
  57. ncbi request reprint Rheolytic thrombectomy with Angiojet in thrombus-containing lesions
    Mandeep Singh
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Catheter Cardiovasc Interv 56:1-7. 2002
    ..It is effective in both native coronary arteries and vein graft interventions. However, the long-term outcome of patients with vein graft intervention was worse...
  58. ncbi request reprint Myocardial bridging in adult patients with hypertrophic cardiomyopathy
    Paul Sorajja
    Division of Cardiovascular Disease and Internal Medicine, Mayo Clinic and Foundation, 200 SW First Street, Rochester, MN 55905, USA
    J Am Coll Cardiol 42:889-94. 2003
    ..This investigation examined the risk of sudden cardiac death and other mortality in adult patients with hypertrophic cardiomyopathy (HCM) who have myocardial bridging diagnosed at coronary angiography...
  59. ncbi request reprint Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention
    Mandeep Singh
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 40:387-93. 2002
    ....
  60. doi request reprint Comparison of drug-eluting and bare-metal stents for stable coronary artery disease
    Brian Horst
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    JACC Cardiovasc Interv 2:321-8. 2009
    ..The current study was designed to determine whether drug-eluting stents (DES) are superior to bare-metal stents (BMS) in patients with stable angina...
  61. ncbi request reprint Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina
    Ahmad A Elesber
    Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Eur Heart J 27:1678-84. 2006
    ....
  62. ncbi request reprint Is the left atrial appendage more than a simple appendage?
    Hidehiko Hara
    Minneapolis Heart Institute and Foundation, Minneapolis, Minnesota, USA
    Catheter Cardiovasc Interv 74:234-42. 2009
    ..The feasibility of this treatment is now established, suggesting that percutaneous therapy is safe, practical and possibly effective to eliminate the need for anticoagulation and significantly reduce cardioembolic events...
  63. ncbi request reprint Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial
    David R Holmes
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 106:1243-50. 2002
    ..No oral agent has shown a beneficial effect on restenosis or on associated major adverse cardiovascular events. In limited trials, the oral agent tranilast has been shown to decrease the frequency of angiographic restenosis after PCI...
  64. ncbi request reprint Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents
    Mandeep Singh
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:1113-8. 2004
    ....
  65. ncbi request reprint Predictors of failure of endovascular therapy for peripheral arterial disease
    Vincent J Yacyshyn
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Angiology 57:403-17. 2006
    ..This coordinate is important in determining the role of restenosis in the clinical failure of endovascular therapy of peripheral arterial disease...
  66. ncbi request reprint Cause of death with bare metal and sirolimus-eluting stents
    David R Holmes
    Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur Heart J 27:2815-22. 2006
    ..The aim of the present study was to compare the incidence and cause of death between patients who received sirolimus-eluting or bare metal stents...
  67. ncbi request reprint Comparison of in-hospital and one-year outcomes in patients with left ventricular ejection fractions <or=40%, 41% to 49%, and >or=50% having percutaneous coronary revascularization
    Paul C Keelan
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Cardiol 91:1168-72. 2003
    ..Thus, significant LV dysfunction was still associated with increased in-hospital and 1-year mortality in patients having contemporary PCI...
  68. ncbi request reprint Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization
    Abhiram Prasad
    Division of Cardiovascular Diseases and Department of Internal Medicine, Rochester, Minn, USA
    Am Heart J 147:1066-70. 2004
    ..The applicability of this subset analysis from a select patient population enrolled in a randomized trial to the general population is unclear...
  69. ncbi request reprint Incidence, retrieval methods, and outcomes of stent loss during percutaneous coronary intervention: a large single-center experience
    Emmanouil S Brilakis
    Division of Cardiovascular Diseases, University of Texas Southwestern Medical Center, Dallas, Texas 75216, USA
    Catheter Cardiovasc Interv 66:333-40. 2005
    ..Stent deployment or crushing may be a good alternative to retrieval...
  70. pmc Lipid-rich plaque masquerading as a coronary thrombus
    Shereif H Rezkalla
    Department of Cardiology, Marshfield Clinic, Marshfield, WI 54449, USA
    Clin Med Res 4:119-22. 2006
    ..Therefore, a stent was placed, and the patient became angina-free. Lipid-rich plaques are a cause of angiographic filling defects. Intravascular ultrasound is an integral part of coronary artery evaluation...
  71. ncbi request reprint Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial
    Mandeep Singh
    Division of Internal Medicine and Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 47:34-9. 2006
    ..In the absence of a definitive clinical trial to support this view, how should the prudent, cutting-edge cardiologist proceed?..
  72. ncbi request reprint Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon
    Cem Barcin
    Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Catheter Cardiovasc Interv 61:484-91. 2004
    ..0 vs. 0.8 +/- 0.6; P < 0.05). Combination therapy of adenosine and nitroprusside is safe and provides better improvement in coronary flow compared to intracoronary adenosine alone in case of impaired flow during coronary interventions...
  73. ncbi request reprint Immediate ambulation following diagnostic coronary angiography procedures utilizing a vascular closure device (The Closer)
    Christopher H Crocker
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Invasive Cardiol 14:728-32. 2002
    ..We investigated the safety and efficacy of The Closer, a suture-mediated vascular closure device, to facilitate immediate ambulation after diagnostic coronary angiography...
  74. doi request reprint Drug-eluting stents in octogenarians: early and intermediate outcome
    Pieter J Vlaar
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 155:680-6. 2008
    ..Large randomized controlled trials have demonstrated that percutaneous coronary intervention with the routine use of drug-eluting stents is safe and effective. However, octogenarians are usually excluded from these trials...
  75. ncbi request reprint Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue
    Deepak R Talreja
    Mayo Graduate School of Medicine, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Am Coll Cardiol 44:2329-32. 2004
    ..This study was designed to evaluate the effect of septal reduction therapies on the conduction system for patients with hypertrophic cardiomyopathy (HCM)...
  76. pmc Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency
    Ayman A El-Menyar
    Department of Cardiology and Cardiovascular Surgery, Hamad General Hospital and Weill Cornell Medical College in Qatar, Doha, Qatar
    Mayo Clin Proc 85:165-71. 2010
    ..In patients with RI, DES implantation yielded better outcomes than did use of bare-metal stents. Randomized trials are needed to define optimal treatment of these high-risk patients with coronary artery disease...